February has brought some noteworthy updates.
⊕ Immuno-oncology:?Bristol Myers Squibb’s latest results show that combining Opdivo? with chemotherapy significantly improved overall survival in certain lung cancer?patients — a promising sign for neoadjuvant therapies. Meanwhile, the FDA’s priority review of zongertinib, a HER2 inhibitor for advanced lung cancer, points to fresh treatment avenues.
⊕ Autoimmunity:?researchers at Penn State have developed an AI tool, the Genetic Progression Score, which forecasts disease progression from the preclinical stage. This could lead to earlier and more effective interventions.
⊕ These developments highlight the growing industry trend towards precision medicine and predictive analytics,?signalling exciting times ahead for both research and clinical application.
?We've also been busy at RoukenBio, with the launch of our advanced targeted integration system: LocIn. Pronounced "loch in" (reflecting our Scottish roots), the system efficiently generates genetically identical isogenic mammalian cell lines, providing?precision, speed, and control in every cell line integration.
Curious? Attend our upcoming webinar with Labroots to learn more about LocIn.
?? Introducing LocIn: RoukenBio's new targeted integration system for the efficient creation of isogenic mammalian cell lines
?? March 18, 2025
?? 4pm GMT
The exciting future of Cell Engineering ??
What’s the future of cell engineering? We caught up with Drs Tim London and Omar Kassaar to talk cell engineering, RoukenBio’s trademark IndEx-2 technology, and to introduce our new targeted integration system – LocIn. Read our interview with the inventors of LocIn.
Spring conference season ??
It's the beginning of Spring and conference season is blossoming. As well as webinars, our brilliant minds will be attending the biggest conferences in biotech, including:?
Interested in our drug discovery services? Pre-book a meeting with us.
Share your thoughts and leave us feedback! ??
Is there anything you would you like to see in our newsletter in the future? Please email your thoughts and suggestions to [email protected].
Best wishes,
The RoukenBio Team
Facilitating scientist to scientist support outsourcing innovative immunological assays. Making it simpler for our customers to succeed.
3 天前Lots of interesting new developments for cell engineering customers. Faster and precise, LocIn sounds very intriguing (and Scottish!)